


Supplementary Fig. S1. (A) Progression-free survival by number of prior lines of therapy. HR, 95% CI, and *P*-value are for line of therapy subgroups versus 0 line subgroup. (B) Progression-free survival by complex karyotype and del(17p) or complex karyotype without del(17p) in the relapsed/refractory setting. HR, 95% CI, and *P*-value are for CK with del(17p) versus CK without del(17p). (C and D) Progression-free survival in patients with and without lymphocytosis at 1 year (C) and 2 years (D). HR, 95% CI, and *P*-value are for lymphocytosis at 1 year versus no lymphocytosis at 1 year (C) or lymphocytosis at 2 years versus no lymphocytosis at 2 years (D). (E) Progression-free survival from day 365 for patients who achieved a CR/PR or PR-L within the first 364 days on study. HR, 95% CI, and *P*-value are for CR/PR versus PR-L. (F) Progression-free survival by age. HR, 95% CI, and *P*-value are for age subgroups versus 0–50 years subgroup.

Progression-free time is calculated as the number of months from first dose date of study treatment to disease progression or death or date of censoring. Patients were censored if they were not assessed as having disease progression by investigators or died at the time of analysis. Tick marks represent censored patients.

CI, confidence interval; CR, complete response; HR, hazard ratio; NE, not estimable; NR, not reached; PR, partial response; PR-L, partial response with lymphocytosis.


A



0 line	31	27	26	26	26	25	25	25	24	24	23	19	18	17	13	9	1	0
1-2 lines	27	24	21	21	20	20	18	16	16	13	12	9	9	8	7	3	2	0
3 lines	14	13	12	10	9	9	9	8	8	7	5	4	4	4	2	2	0	0
≥4 lines	60	49	45	41	34	29	27	20	17	14	12	11	9	7	6	3	1	0


	Median, months (95% CI)	7-year PFS	HR (95% CI) P-value
0 lines of therapy (n=31)	NR (NE-NE)	83%	—
1-2 lines of therapy (n=27)	66 (37-NE)	41%	5.019 (1.632-15.434) P=0.005
3 lines of therapy (n=14)	59 (22-NE)	49%	4.671 (1.314-16.597) P=0.017
≥4 lines of therapy (n=60)	39 (26-51)	28%	9.506 (3.366-26.846) P<0.001

B



	Median, months (95% CI)	7-year PFS	HR (95% CI) P-value
CK with del(17p)(n=22)	25 (12-33)	13%	3.632 (1.408-9.371) P=0.008
CK without del(17p)(n=15)	88 (14-NE)	50%	


C




Lymphocytosis at 1 year	54	54	50	48	46	44	43	38	37	32	27	23	21	20	17	11	2	0
No lymphocytosis at 1 year	78	59	54	50	43	39	36	31	28	26	25	20	19	16	11	6	2	0

	Median, months (95% CI)	7-year PFS	HR (95% CI) <i>P</i> -value
Lymphocytosis at 1 year (n=54)	92 (59-NE)	54%	0.566 (0.330-0.935) <i>P</i> =0.027
No lymphocytosis at 1 year (n=78)	52 (33-87)	39%	

D




E



CR/PR	75	70	63	58	57	55	49	47	40	38	33	28	27	24	22	13	8	1	0
PR-L	24	24	24	24	22	21	18	18	18	15	13	11	11	10	9	8	6	3	0

	Median, months (95% CI)	7-year PFS	HR (95% CI) P-value
CR/PR (n=75)	87 (66-NE)	53%	1.068 (0.549-2.078) P=0.846
PR-L (n=24)	92 (55-NE)	51%	

F



	Median, months (95% CI)	7-year PFS	HR (95% CI) P-value
0-50 years (n=9)	20 (1-37)	16%	—
>50-60 years (n=32)	52 (32-87)	32%	0.456 (0.179-1.164) P=0.101
>60-70 years (n=47)	92 (43-NE)	51%	0.276 (0.110-0.693) P=0.006
>70-80 years (n=40)	NR (63-NE)	61%	0.217 (0.082-0.573) P=0.002
>80 years (n=4)	37 (18-70)	0%	0.817 (0.204-3.276) P=0.775